vs

Side-by-side financial comparison of Easterly Government Properties, Inc. (DEA) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

Easterly Government Properties, Inc. is the larger business by last-quarter revenue ($91.5M vs $75.5M, roughly 1.2× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 16.4%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 9.6%).

Easterly Government Properties, Inc. is a U.S.-headquartered real estate investment trust focused on acquiring, developing, and managing mission-critical commercial properties primarily leased to U.S. federal government agencies. Its portfolio covers office spaces, healthcare facilities, and security-related properties, serving government clients across key domestic markets.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

DEA vs PBYI — Head-to-Head

Bigger by revenue
DEA
DEA
1.2× larger
DEA
$91.5M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+11.4% gap
PBYI
27.7%
16.4%
DEA
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
9.6%
DEA

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DEA
DEA
PBYI
PBYI
Revenue
$91.5M
$75.5M
Net Profit
$1.4M
Gross Margin
69.3%
Operating Margin
22.7%
Net Margin
1.5%
Revenue YoY
16.4%
27.7%
Net Profit YoY
-56.9%
EPS (diluted)
$0.36
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DEA
DEA
PBYI
PBYI
Q1 26
$91.5M
Q4 25
$87.0M
$75.5M
Q3 25
$86.2M
$54.5M
Q2 25
$84.2M
$52.4M
Q1 25
$78.7M
$46.0M
Q4 24
$78.3M
$59.1M
Q3 24
$74.8M
$80.5M
Q2 24
$76.2M
$47.1M
Net Profit
DEA
DEA
PBYI
PBYI
Q1 26
$1.4M
Q4 25
$4.6M
Q3 25
$1.2M
$8.8M
Q2 25
$4.1M
$5.9M
Q1 25
$3.1M
$3.0M
Q4 24
$5.5M
Q3 24
$4.9M
$20.3M
Q2 24
$4.6M
$-4.5M
Gross Margin
DEA
DEA
PBYI
PBYI
Q1 26
Q4 25
77.3%
69.3%
Q3 25
76.0%
77.7%
Q2 25
77.2%
76.5%
Q1 25
77.4%
77.1%
Q4 24
76.1%
76.4%
Q3 24
77.7%
63.9%
Q2 24
76.2%
77.4%
Operating Margin
DEA
DEA
PBYI
PBYI
Q1 26
Q4 25
22.7%
Q3 25
17.6%
Q2 25
12.7%
Q1 25
8.7%
Q4 24
22.6%
Q3 24
27.4%
Q2 24
-4.6%
Net Margin
DEA
DEA
PBYI
PBYI
Q1 26
1.5%
Q4 25
5.3%
Q3 25
1.4%
16.2%
Q2 25
4.8%
11.2%
Q1 25
4.0%
6.5%
Q4 24
7.0%
Q3 24
6.5%
25.2%
Q2 24
6.0%
-9.6%
EPS (diluted)
DEA
DEA
PBYI
PBYI
Q1 26
$0.36
Q4 25
$0.09
$0.26
Q3 25
$0.02
$0.17
Q2 25
$0.09
$0.12
Q1 25
$0.07
$0.06
Q4 24
$0.13
$0.40
Q3 24
$0.11
$0.41
Q2 24
$0.11
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DEA
DEA
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$2.0M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$1.3B
$130.3M
Total Assets
$3.4B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DEA
DEA
PBYI
PBYI
Q1 26
$2.0M
Q4 25
$23.4M
$97.5M
Q3 25
$4.4M
$94.4M
Q2 25
$4.7M
$96.0M
Q1 25
$8.5M
$93.2M
Q4 24
$19.4M
$101.0M
Q3 24
$31.2M
$96.7M
Q2 24
$14.8M
$96.8M
Total Debt
DEA
DEA
PBYI
PBYI
Q1 26
Q4 25
$1.7B
$22.7M
Q3 25
$1.6B
$34.0M
Q2 25
$1.7B
$45.3M
Q1 25
$1.6B
$56.7M
Q4 24
$1.6B
$68.0M
Q3 24
$1.5B
$79.3M
Q2 24
$1.4B
$90.7M
Stockholders' Equity
DEA
DEA
PBYI
PBYI
Q1 26
$1.3B
Q4 25
$1.3B
$130.3M
Q3 25
$1.3B
$115.3M
Q2 25
$1.3B
$104.7M
Q1 25
$1.3B
$97.1M
Q4 24
$1.3B
$92.1M
Q3 24
$1.3B
$71.1M
Q2 24
$1.3B
$48.5M
Total Assets
DEA
DEA
PBYI
PBYI
Q1 26
$3.4B
Q4 25
$3.4B
$216.3M
Q3 25
$3.4B
$202.9M
Q2 25
$3.4B
$194.9M
Q1 25
$3.2B
$196.2M
Q4 24
$3.2B
$213.3M
Q3 24
$3.1B
$220.7M
Q2 24
$3.0B
$205.0M
Debt / Equity
DEA
DEA
PBYI
PBYI
Q1 26
Q4 25
1.26×
0.17×
Q3 25
1.23×
0.30×
Q2 25
1.29×
0.43×
Q1 25
1.20×
0.58×
Q4 24
1.21×
0.74×
Q3 24
1.12×
1.12×
Q2 24
1.07×
1.87×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DEA
DEA
PBYI
PBYI
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.7%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DEA
DEA
PBYI
PBYI
Q1 26
Q4 25
$259.2M
$14.4M
Q3 25
$155.0M
$9.7M
Q2 25
$38.1M
$14.1M
Q1 25
$24.2M
$3.6M
Q4 24
$162.6M
$15.6M
Q3 24
$57.2M
$11.0M
Q2 24
$57.0M
$1.0M
Free Cash Flow
DEA
DEA
PBYI
PBYI
Q1 26
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
FCF Margin
DEA
DEA
PBYI
PBYI
Q1 26
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Capex Intensity
DEA
DEA
PBYI
PBYI
Q1 26
0.7%
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Cash Conversion
DEA
DEA
PBYI
PBYI
Q1 26
Q4 25
56.44×
Q3 25
127.75×
1.10×
Q2 25
9.36×
2.41×
Q1 25
7.73×
1.21×
Q4 24
29.82×
Q3 24
11.76×
0.54×
Q2 24
12.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DEA
DEA

Rental income$88.6M97%
Other$2.3M3%
Asset management income$646.0K1%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons